相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond
Jean-Luc Raoul et al.
CANCER TREATMENT REVIEWS (2018)
Sorafenib paradoxically activates the RAS/RAF/ERK pathway in polyclonal human NK cells during expansion and thereby enhances effector functions in a dose- and time-dependent manner
J. Lohmeyer et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2018)
Combinational immune-cell therapy of natural killer cells and sorafenib for advanced hepatocellular carcinoma: a review
Faezeh Hosseinzadeh et al.
CANCER CELL INTERNATIONAL (2018)
Immunotherapy of Hepatocellular Carcinoma: Facts and Hopes
Mercedes Inarrairaegui et al.
CLINICAL CANCER RESEARCH (2018)
Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials
Masatoshi Kudo
ONCOLOGY (2017)
Sorafenib: A Review in Hepatocellular Carcinoma
Gillian M. Keating
TARGETED ONCOLOGY (2017)
Pyroptosis: Gasdermin-Mediated Programmed Necrotic Cell Death
Jianjin Shi et al.
TRENDS IN BIOCHEMICAL SCIENCES (2017)
The Inflammasome Drives GSDMD-Independent Secondary Pyroptosis and IL-1 Release in the Absence of Caspase-1 Protease Activity
Katharina S. Schneider et al.
CELL REPORTS (2017)
Natural killer cells in hepatocellular carcinoma: current status and perspectives for future immunotherapeutic approaches
Min Yu et al.
FRONTIERS OF MEDICINE (2017)
The Impact of Early Dermatologic Events in the Survival of Patients with Hepatocellular Carcinoma Treated with Sorafenib
Fernanda Branco et al.
ANNALS OF HEPATOLOGY (2017)
Design and Reporting of Targeted Anticancer Preclinical Studies: A Meta-Analysis of Animal Studies Investigating Sorafenib Antitumor Efficacy
James Mattina et al.
CANCER RESEARCH (2016)
Small-molecule inhibitor sorafenib regulates immunoreactions by inducing survival and differentiation of bone marrow cells
Xiangxuan Zhao et al.
INNATE IMMUNITY (2016)
Fever within 2 Weeks of Sorafenib Therapy Predicts Favorable Treatment Efficacy in Patients with Advanced Hepatocellular Carcinoma
Teiji Kuzuya et al.
ONCOLOGY (2016)
Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy
Cheng Sun et al.
ACTA PHARMACOLOGICA SINICA (2015)
CXCR4 Inhibition in Tumor Microenvironment Facilitates Anti-Programmed Death Receptor-1 Immunotherapy in Sorafenib-Treated Hepatocellular Carcinoma in Mice
Yunching Chen et al.
HEPATOLOGY (2015)
Inflammasomes Coordinate Pyroptosis and Natural Killer Cell Cytotoxicity to Clear Infection by a Ubiquitous Environmental Bacterium
Vivien I. Maltez et al.
IMMUNITY (2015)
Sorafenib inhibits macrophage-induced growth of hepatoma cells by interference with insulin-like growth factor-1 secretion
Martin Franz Sprinzl et al.
JOURNAL OF HEPATOLOGY (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy
Carola H. Ries et al.
CANCER CELL (2014)
An Inducible Hepatocellular Carcinoma Model for Preclinical Evaluation of Antiangiogenic Therapy in Adult Mice
Anja Runge et al.
CANCER RESEARCH (2014)
Interplay Between Cancer Cells, Macrophages and Natural Killer Cells May Actually Decide the Outcome of Therapy With Sorafenib
Ciprian Tomuleasa et al.
HEPATOLOGY (2014)
Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity
Mei-Ling Chen et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib
Maria Reig et al.
JOURNAL OF HEPATOLOGY (2014)
Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma
Masayoshi Yada et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Pro-apoptotic Sorafenib signaling in murine hepatocytes depends on malignancy and is associated with PUMA expression in vitro and in vivo
R. Sonntag et al.
CELL DEATH & DISEASE (2014)
Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells
Martin Franz Sprinzl et al.
HEPATOLOGY (2013)
NK Cells Prevalence, Subsets and Function in Viral Hepatitis C
Jan Zeromski et al.
ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS (2011)
Bridging from Preclinical to Clinical Studies for Tyrosine Kinase Inhibitors Based on Pharmacokinetics/Pharmacodynamics and Toxicokinetics/Toxicodynamics
Azusa Hoshino-Yoshino et al.
DRUG METABOLISM AND PHARMACOKINETICS (2011)
Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma
Antonia Busse et al.
EUROPEAN JOURNAL OF CANCER (2011)
Caspase-1-induced pyroptotic cell death
Edward A. Miao et al.
IMMUNOLOGICAL REVIEWS (2011)
Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model
Mengde Cao et al.
LABORATORY INVESTIGATION (2011)
Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
Kristy J. Gotink et al.
ANGIOGENESIS (2010)
Sorafenib Inhibits the Shedding of Major Histocompatibility Complex Class I-Related Chain A on Hepatocellular Carcinoma Cells by Down-Regulating a Disintegrin and Metalloproteinase 9
Keisuke Kohga et al.
HEPATOLOGY (2010)
Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients
Valerie Chew et al.
JOURNAL OF HEPATOLOGY (2010)
Tumor agonist peptides break tolerance and elicit effective CTL responses in an inducible mouse model of hepatocellular carcinoma
Simone Stahl et al.
IMMUNOLOGY LETTERS (2009)
The Kinase Inhibitors Sunitinib and Sorafenib Differentially Affect NK Cell Antitumor Reactivity In Vitro
Matthias Krusch et al.
JOURNAL OF IMMUNOLOGY (2009)
Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses
Madeleine M. Hipp et al.
BLOOD (2008)
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
Scott M. Wilhelm et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Do autochthonous tumors interfere with effector T cell responses?
Thomas Blankenstein
SEMINARS IN CANCER BIOLOGY (2007)
Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors
D Strumberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
分享论文
